We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts Launches Clinical Pathways for Cancer Treatment
Read MoreHide Full Article
Renowned information technology and services provider to healthcare organizations Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) recently announced the launch of Clinical Pathways program for the treatment of cancer. The platform was launched in collaboration with Cancer Treatment Centers of America (CTCA), a national network of five hospitals that serve adult cancer patients and NantHealth, a member of the NantWorks ecosystem of companies.
In a nutshell, the newly launched Clinical Pathways program unifies the latest technologies for cancer care, treatment regimens and complementary therapy options into Allscripts’ flagship Sunrise Electronic Health Record (EHR) platform. In this regard, Sunrise is a highly configurable electronic health record platform that offers workflows to drive clinical decision support.
Of late, this platform has contributed significantly to the company’s topline performance. In fact, in the just-reported fourth quarter, Allscripts witnessed an 18% rise in its net bookings, solely driven by solid sales at the Sunrise platform in the U.S. and international markets.
Meanwhile, Allscripts gained 1.7% to close at $12.22 following the news. Furthermore, over the last three months, the price performance of Allscipts has been encouraging. The stock added 11.6%, comparing favorably with the Zacks classified Medical Info Systems sub-industry’s gain of 9.1%. Also, the current level compares favorably with the S&P 500’s return of 6.4% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been dismal. The full year has seen seven analysts move south over the last one month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year dropped 4% to 47 cents over the same time frame. Notably, the stock has Zacks Rank #3 (Hold).
Getting back to the development, apart from Allscripts’ Sunrise, Clinical Pathaways will also leverage on eviti, a NantHealth clinical decision support platform. Clinical Pathways will be available for use at all five CTCA hospital locations.
We are upbeat on the latest developments in the broader EHR market. Notably, a report by Transparency Market research suggests that the global EHR market is projected to reach a worth of nearly $24 billion by 2020, fueled by steady growth in the increased R&D activities across the sector over the long haul. Meanwhile, Allscripts’ stock promises a long-term expected earnings growth rate of 16.5%, instilling confidence in investors.
Glaukos has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 181.3%.
Avinger projects sales growth of 2.3% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock has added 13.5% over the last three months.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Allscripts Launches Clinical Pathways for Cancer Treatment
Renowned information technology and services provider to healthcare organizations Allscripts Healthcare Solutions, Inc. (MDRX - Free Report) recently announced the launch of Clinical Pathways program for the treatment of cancer. The platform was launched in collaboration with Cancer Treatment Centers of America (CTCA), a national network of five hospitals that serve adult cancer patients and NantHealth, a member of the NantWorks ecosystem of companies.
In a nutshell, the newly launched Clinical Pathways program unifies the latest technologies for cancer care, treatment regimens and complementary therapy options into Allscripts’ flagship Sunrise Electronic Health Record (EHR) platform. In this regard, Sunrise is a highly configurable electronic health record platform that offers workflows to drive clinical decision support.
Of late, this platform has contributed significantly to the company’s topline performance. In fact, in the just-reported fourth quarter, Allscripts witnessed an 18% rise in its net bookings, solely driven by solid sales at the Sunrise platform in the U.S. and international markets.
Meanwhile, Allscripts gained 1.7% to close at $12.22 following the news. Furthermore, over the last three months, the price performance of Allscipts has been encouraging. The stock added 11.6%, comparing favorably with the Zacks classified Medical Info Systems sub-industry’s gain of 9.1%. Also, the current level compares favorably with the S&P 500’s return of 6.4% over the same time frame.
Despite the bullish price trend, estimate revision for the stock has been dismal. The full year has seen seven analysts move south over the last one month, with no movement in the opposite direction. As a result, the Zacks Consensus Estimate for the full year dropped 4% to 47 cents over the same time frame. Notably, the stock has Zacks Rank #3 (Hold).
Getting back to the development, apart from Allscripts’ Sunrise, Clinical Pathaways will also leverage on eviti, a NantHealth clinical decision support platform. Clinical Pathways will be available for use at all five CTCA hospital locations.
Allscripts Healthcare Solutions, Inc. Price
Allscripts Healthcare Solutions, Inc. Price | Allscripts Healthcare Solutions, Inc. Quote
Our Take
We are upbeat on the latest developments in the broader EHR market. Notably, a report by Transparency Market research suggests that the global EHR market is projected to reach a worth of nearly $24 billion by 2020, fueled by steady growth in the increased R&D activities across the sector over the long haul. Meanwhile, Allscripts’ stock promises a long-term expected earnings growth rate of 16.5%, instilling confidence in investors.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Glaukos Corp. (GKOS - Free Report) , Avinger, Inc. (AVGR - Free Report) and Fluidigm Corp. . Notably, Glaukos sports a Zacks Rank #1 (Strong Buy), while Avinger and Fluidigm have Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 181.3%.
Avinger projects sales growth of 2.3% for the current year. Additionally, the company posted a positive earnings surprise of 27% in the last quarter.
Fluidigm has a long-term expected earnings growth rate of 25%. The stock has added 13.5% over the last three months.
A Full-Blown Technological Breakthrough in the Making
Zacks’ Aggressive Growth Strategist Brian Bolan explores autonomous cars in our latest Special Report, Driverless Cars: Your Roadmap to Mega-Profits Today. In addition to who will be selling them and how the auto industry will be impacted, Brian reveals 8 stocks with tremendous gain potential to feed off this phenomenon. Click to see the stocks right now >>